Laddar...
IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines
The recent RESORCE trial showed that treatment with Regorafenib after Sorafenib failure provided a significant improvement in overall survival in HCC patients. Preclinical and clinical trial data showed that Regorafenib is a more potent drug than Sorafenib. In this study we aimed at improving Regora...
Sparad:
| I publikationen: | Oncotarget |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Impact Journals LLC
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5732742/ https://ncbi.nlm.nih.gov/pubmed/29262576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21403 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|